Literature DB >> 9541344

Propofol and fentanyl compared with midazolam and fentanyl during third molar surgery.

L P Parworth1, D E Frost, J R Zuniga, T Bennett.   

Abstract

PURPOSE: The purpose of this study was to measure the safety and efficacy of propofol combined with fentanyl as sedative agents during third molar outpatient surgery. PATIENTS AND METHODS: A double-blind, prospective, randomized clinical trial involving 57 patients undergoing removal of third molars under intravenous sedation between November 1994 and December 1995 was performed. Patients randomly received either propofol and fentanyl (P + F, th = 24) or midazolam and fentanyl (M + F, M = 33). Patient demographics, Corah anxiety scores, and physiologic parameters were determined preoperatively. All medications were titrated to the same clinical end point for sedation. Intraoperative physiologic parameters, cooperation, alertness, and pain scores were assessed. Postoperative recovery and degree of amnesia also were determined.
RESULTS: There were no significant differences in either patient demographics or surgical characteristics between groups. The P + F group was significantly less cooperative than the M + F group. Pain during injection of propofol was a significant adverse side effect. Both groups experienced a small percentage of apneic episodes, but mechanical ventilation was never required. There were no differences in recovery between groups as measured by the Treiger dot test and psychomotor recovery scores. The degree of anterograde amnesia was greater for the M + F group, although the difference was not statistically significant. Sedation was rated good to excellent by the patient, surgeon, and observer, and there were no statistically significant differences between groups.
CONCLUSION: Propofol appears to be a safe and efficacious drug for use during outpatient oral surgical procedures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541344     DOI: 10.1016/s0278-2391(98)90710-8

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  7 in total

1.  An evaluation of analgesic efficacy and clinical acceptability of intravenous tramadol as an adjunct to propofol sedation for third molar surgery.

Authors:  E A Shipton; J A Roelofse; R J Blignaut
Journal:  Anesth Prog       Date:  2003

2.  Comparitive Evaluation of Propofol and Midazolam as Conscious Sedatives in Minor Oral Surgery.

Authors:  P Hari Keerthy; Ramdas Balakrishna; Krishna Mohan Srungeri; Nikhil Singhvi; Joseph John; Mueedul Islam
Journal:  J Maxillofac Oral Surg       Date:  2014-09-02

3.  Comparative Study Between Oral Lorazepam and Diazepam as Sedation in Oral and Maxillofacial Surgery.

Authors:  Vikas Sharma; Amaninder Singh; Parul Sharma; Simranjeet Kaur; Akanksha Zutshi
Journal:  J Maxillofac Oral Surg       Date:  2018-03-05

4.  Comparative Analysis of Intravenous Midazolam with Nasal Spray for Conscious Sedation in Minor Oral and Maxillofacial Surgeries.

Authors:  Ramesh Kunusoth; Gururam Tej; Kranti Kiran Reddy Ealla; Pavan Kumar Kathuroju; Anusha Ayyagari; Aditya Mohan Alwala
Journal:  J Pharm Bioallied Sci       Date:  2019-02

5.  Comparative Evaluation of the Intranasal Spray Formulation of Midazolam and Dexmedetomidine in Patients Undergoing Surgical Removal of Impacted Mandibular Third Molars: A Split Mouth Prospective Study.

Authors:  Shashank Hiwarkar; Rajesh Kshirsagar; Vikram Singh; Amod Patankar; Sanjay Chandan; Mukund Rathod; Ajay Mohite
Journal:  J Maxillofac Oral Surg       Date:  2016-12-18

6.  Quality of life following third molar removal under conscious sedation.

Authors:  Manuel Sancho-Puchades; Eduard Valmaseda-Castellón; Leonardo Berini-Aytés; Cosme Gay-Escoda
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-11-01

7.  Comparison of dexmedetomidine with midazolam for dental surgery: A systematic review and meta-analysis.

Authors:  Yibo Zhang; Chao Li; Jingjing Shi; Yanming Gong; Tao Zeng; Min Lin; Xi Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.